{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:27:27Z","timestamp":1790832447096,"version":"4.1.0"},"reference-count":213,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01243","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T06:20:37Z","timestamp":1595917237000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":76,"title":["CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions"],"prefix":"10.3389","volume":"10","author":[{"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Ganzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hudecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Danhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/0006-291x(87)90502-x","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived v regions and T-cell receptor-derived c regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"key":"B7","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/gt.2010.21","article-title":"Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the lewis Y antigen","volume":"17","author":"Peinert","year":"2010","journal-title":"Gene Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR) -modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/ijc.31147","article-title":"Chimeric Antigen receptor transduced t cells: tuning up for the next generation","volume":"142","author":"Schubert","year":"2018","journal-title":"Int J Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The Urgent need to recover MHC class i in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr Opin Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/gt.2012.48","article-title":"Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma","volume":"20","author":"Schuberth","year":"2013","journal-title":"Gene Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.molimm.2004.06.041","article-title":"The BAFF\/APRIL system: life beyond B lymphocytes","volume":"42","author":"Ng","year":"2005","journal-title":"Mol Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.coph.2004.02.009","article-title":"The role of the BAFF\/APRIL system in B cell homeostasis and lymphoid cancers","volume":"4","author":"Mackay","year":"2004","journal-title":"Curr Opin Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest."},{"key":"B19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J Exp Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1600-065X.2011.01067.x","article-title":"Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease","volume":"244","author":"Rickert","year":"2011","journal-title":"Immunol Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF and APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu Rev Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.4049\/jimmunol.180.6.3655","article-title":"Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and april","volume":"180","author":"Benson","year":"2008","journal-title":"J Immunol. Baltim. Md."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/blood-2007-09-110858","article-title":"APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells","volume":"111","author":"Belnoue","year":"2008","journal-title":"Blood."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1128\/MCB.21.12.4067-4074.2001","article-title":"B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses","volume":"21","author":"Xu","year":"2001","journal-title":"Mol Cell Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus A plasmablastic signature","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0609.2009.01262.x","article-title":"APRIL, and TACI Interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop","volume":"83","author":"Moreaux","year":"2009","journal-title":"Eur J Haematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","article-title":"Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model","volume":"13","author":"Neri","year":"2007","journal-title":"Clin Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1182\/blood-2013-09-529800","article-title":"Robust isolation of malignant plasma cells in multiple myeloma","volume":"123","author":"Frigyesi","year":"2014","journal-title":"Blood."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood.V100.4.1113.h81602001113_1113_1122","article-title":"Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts","volume":"100","author":"Tarte","year":"2002","journal-title":"Blood."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1182\/blood-2002-01-0008","article-title":"A molecular compendium of genes expressed in multiple myeloma","volume":"100","author":"Claudio","year":"2002","journal-title":"Blood."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1182\/blood-2003-07-2559","article-title":"Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens","volume":"103","author":"Bellucci","year":"2004","journal-title":"Blood."},{"key":"B38","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"Secretase directly sheds the survival receptor BCMA from plasma cells","author":"Laurent","year":"2015","journal-title":"Nat Commun.6"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","article-title":"Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e24313","DOI":"10.1200\/JCO.2018.36.15\/suppl.e24313","article-title":"Serum B-cell maturation antigen levels to predict progression free survival and responses among relapsed or refractory multiple myeloma patients treated on the phase i IRUX trial","volume":"36","author":"Bujarski","year":"2018","journal-title":"J Clin Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","article-title":"Serum B-cell maturation antigen (BCMA) reduces binding of ANTI-BCMA antibody to multiple myeloma cells","volume":"81","author":"Chen","year":"2019","journal-title":"Leuk Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2019-124953","article-title":"Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) Cell therapy targeting B-cell maturation antigen (BCMA), in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Wang","year":"2019","journal-title":"Blood."},{"key":"B47","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B48","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE-1: A phase 1b\/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and\/or refractory multiple myeloma (R\/R MM)","volume":"134","author":"Madduri","year":"2019","journal-title":"Blood."},{"key":"B49","doi-asserted-by":"publisher","first-page":"8505","DOI":"10.1200\/JCO.2020.38.15\/suppl.8505","article-title":"Update of cartitude-1: A phase Ib\/II study of JNJ-4528, a B-cell maturation antigen (BCMA) -directed CAR-T-cell therapy, in relapsed\/refractory multiple myeloma","volume":"38","author":"Berdeja","year":"2020","journal-title":"J Clin Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy Bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med."},{"key":"B52","unstructured":"2019"},{"key":"B53","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1200\/JCO.2020.38.15\/suppl.8503","article-title":"Idecabtagene vicleucel (Ide-Cel; Bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial Kar MMa results","volume":"38","author":"Munshi","year":"2020","journal-title":"J Clin Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood-2019-126660","article-title":"Updated results from an ongoing phase 1 clinical study of Bb21217 anti-bcma CAR T cell therapy","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood."},{"key":"B55","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125 A, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: initial proof of concept results from a Phase 1\/2 multicenter study (EVOLVE)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood."},{"key":"B56","doi-asserted-by":"publisher","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15\/suppl.8504","article-title":"Orvacabtagene autoleucel (Orva-Cel), a B-cell maturation antigen (BCMA) -directed CAR T cell therapy for patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J Clin Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: final results of a phase i clinical trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1182\/blood-2018-99-111419","article-title":"Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM)","volume":"132","author":"Gregory","year":"2018","journal-title":"Blood."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1182\/blood-2019-129562","article-title":"Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME)","volume":"134","author":"Costello","year":"2019","journal-title":"Blood."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood-2018-99-116898","article-title":"T cells expressing anti B-cell maturation antigen chimeric antigen receptors for plasma cell malignancies","volume":"132","author":"Li","year":"2018","journal-title":"Blood."},{"key":"B62","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1182\/blood-2019-126104","article-title":"Phase 1 trial of the safety and efficacy of fully human anti-Bcma CAR T cells in relapsed\/refractory multiple myeloma","volume":"134","author":"Jie","year":"2019","journal-title":"Blood."},{"key":"B63","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1182\/blood-2019-128468","article-title":"Efficacy and safety of fully human Bcma targeting CAR T cell therapy in relapsed\/refractory multiple myeloma","volume":"134","author":"Li","year":"2019","journal-title":"Blood."},{"key":"B64","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1182\/blood-2019-129088","article-title":"T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-only antigen recognition domain induce remissions in patients with relapsed multiple myeloma","volume":"134","author":"Mikkilineni","year":"2019","journal-title":"Blood."},{"key":"B65","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat. Commun."},{"key":"B66","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1182\/blood-2018-99-112786","article-title":"Durable remission achieved from Bcma-Directed CAR-T therapy against relapsed or refractory multiple myeloma","volume":"132","author":"Liu","year":"2018","journal-title":"Blood."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood."},{"key":"B68","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1182\/blood-2019-127309","article-title":"Translational analysis from CARTITUDE-1, an ongoing phase 1b\/2 study of JNJ-4528 BCMA-targeted CAR-T cell therapy in relapsed and\/or refractory multiple myeloma (R\/R MM), indicates preferential expansion of CD8+ T cell central memory cell subset","volume":"134","author":"Zudaire","year":"2019","journal-title":"Blood."},{"key":"B69","doi-asserted-by":"publisher","first-page":"25764","DOI":"10.18632\/oncotarget.25359","article-title":"Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma","volume":"9","author":"Bu","year":"2018","journal-title":"Oncotarget."},{"key":"B70","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"B71","unstructured":"2018"},{"key":"B72","unstructured":"2020"},{"key":"B73","unstructured":"2019"},{"key":"B74","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e95103","DOI":"10.1172\/jci.insight.95103","article-title":"Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy","volume":"2","author":"Klebanoff","year":"2017","journal-title":"JCI Insight."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","article-title":"Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector","volume":"26","author":"Smith","year":"2018","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e127684","DOI":"10.1172\/jci.insight.127684","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"4","author":"Garfall","year":"2019","journal-title":"JCI Insight."},{"key":"B80","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1038\/s41467-019-10948-w","article-title":"Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T.","volume":"10","author":"Nerreter","year":"2019","journal-title":"Nat. Commun."},{"key":"B81","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/leu.2016.211","article-title":"Differentiation stage of myeloma plasma cells: biological and clinical significance","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood-2018-99-117964","article-title":"Tandom autologous transplantation and combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for high risk MM: initial safety and efficacy report from a clinical pilot study","volume":"132","author":"Shi","year":"2018","journal-title":"Blood."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1 a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody huluc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood."},{"key":"B87","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.imlet.2010.09.021","article-title":"Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells","volume":"134","author":"De Salort","year":"2011","journal-title":"Immunol Lett."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.3389\/fimmu.2018.02551","article-title":"Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma","volume":"9","author":"Campbell","year":"2018","journal-title":"Front Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"a002469","DOI":"10.1101\/cshperspect.a002469","article-title":"SLAM-family receptors: immune regulators with or without SAP-family adaptors","volume":"2","author":"Veillette","year":"2010","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature22076","article-title":"SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin","volume":"544","author":"Chen","year":"2017","journal-title":"Nature."},{"key":"B91","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood."},{"key":"B93","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/leu.2016.180","article-title":"Enhanced CAR T-cell engineering using non-viral sleeping beauty transposition from minicircle vectors","volume":"31","author":"Monjezi","year":"2017","journal-title":"Leukemia."},{"key":"B94","doi-asserted-by":"publisher","first-page":"675009","DOI":"10.1101\/675009","article-title":"Genomic analyses of SLAMF7 CAR-T cells manufactured by sleeping beauty transposon gene transfer for immunotherapy of multiple myeloma","author":"Miskey","year":"2019","journal-title":"bioRxiv."},{"key":"B95","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1182\/blood.V130.Suppl\/1.502.502","article-title":"Universal SLAMF7-Specific CAR T-cells as treatment for multiple myeloma","volume":"130","author":"Mathur","year":"2017","journal-title":"Blood."},{"key":"B96","first-page":"489","article-title":"CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q","volume":"90","author":"Liebisch","year":"2005","journal-title":"Haematologica."},{"key":"B97","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3389\/fimmu.2018.00507","article-title":"Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional CAR-T cells co-expressing a suicide gene","volume":"9","author":"Casucci","year":"2018","journal-title":"Front Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T Cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","article-title":"A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus","volume":"12","author":"Tijink","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1182\/blood-2018-99-117974","article-title":"Phase I-IIa clinical trial to assess safety and efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in relapsed\/refractory acute myeloid leukemia (AML) and multiple myeloma (MM)","volume":"132","author":"Carrabba","year":"2018","journal-title":"Blood."},{"key":"B101","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3892\/ijo.2012.1545","article-title":"Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide","volume":"41","author":"Kawano","year":"2012","journal-title":"Int J Oncol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00277-017-3029-3","article-title":"Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement","volume":"96","author":"Tian","year":"2017","journal-title":"Ann. Hematol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.matbio.2013.10.005","article-title":"Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse","volume":"35","author":"Ramani","year":"2014","journal-title":"Matrix Biol J Int Soc Matrix Biol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/gt.2010.174","article-title":"Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T Cells","volume":"18","author":"Barber","year":"2011","journal-title":"Gene Ther."},{"key":"B105","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood."},{"key":"B107","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.molimm.2015.04.013","article-title":"Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma","volume":"67","author":"Hutchinson","year":"2015","journal-title":"Mol Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol Baltim Md."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered t cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica."},{"key":"B116","doi-asserted-by":"publisher","first-page":"e0197349","DOI":"10.1371\/journal.pone.0197349","article-title":"Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design","volume":"13","author":"Drent","year":"2018","journal-title":"PLoS ONE."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1182\/blood-2019-131892","article-title":"Development of an allogeneic anti-Bcma T cell therapy utilizing a novel dimeric antigen receptor (DAR) structure","volume":"134","author":"Ding","year":"2019","journal-title":"Blood."},{"key":"B118","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G Protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest."},{"key":"B119","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","article-title":"GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells","volume":"18","author":"Cohen","year":"2013","journal-title":"Hematol Amst Neth."},{"key":"B120","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1182\/blood-2019-126145","article-title":"Optimal dual-targeted CAR construct simultaneously targeting Bcma and GPRC5D prevents Bcma-escape driven relapse in multiple myeloma","volume":"134","author":"Fernandez de Larrea","year":"2019","journal-title":"Blood."},{"key":"B122","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood.V76.2.377.377","article-title":"Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19)","volume":"76","author":"Van Camp","year":"1990","journal-title":"Blood."},{"key":"B123","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.clml.2018.08.018","article-title":"A phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and\/or refractory CD-56-positive multiple myeloma","volume":"19","author":"Ailawadhi","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B124","doi-asserted-by":"publisher","first-page":"e17572","DOI":"10.1097\/MD.0000000000017572","article-title":"CD56-chimeric antigen receptor T-cell therapy for refractory\/recurrent rhabdomyosarcoma: a 3.5-year follow-up case report","volume":"98","author":"Jiang","year":"2019","journal-title":"Medicine."},{"key":"B125","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/1538-7445.AM2012-3499","article-title":"CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma","volume":"72","author":"Benjamin","year":"2012","journal-title":"Cancer Res."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(06)95001-5","article-title":"NY-ESO-1: review of an immunogenic tumor antigen","volume":"95","author":"Gnjatic","year":"2006","journal-title":"Adv Cancer Res."},{"key":"B127","first-page":"9","article-title":"Expression of cancer\/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease","volume":"3","author":"Dhodapkar","year":"2003","journal-title":"Cancer Immun."},{"key":"B128","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1182\/blood-2004-09-3707","article-title":"NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses","volume":"105","author":"van Rhee","year":"2005","journal-title":"Blood."},{"key":"B129","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1182\/bloodadvances.2019000194","article-title":"Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma","volume":"3","author":"Stadtmauer","year":"2019","journal-title":"Blood Adv."},{"key":"B131","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood-2016-08-732636","article-title":"NY-ESO-1 TCR single edited stem and central memory t cells to treat multiple myeloma without graft-versus-host disease","volume":"130","author":"Mastaglio","year":"2017","journal-title":"Blood."},{"key":"B132","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1182\/blood-2019-130340","article-title":"A bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed\/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial","volume":"134","author":"Li","year":"2019","journal-title":"Blood."},{"key":"B133","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1182\/blood-2019-126689","article-title":"Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Popat","year":"2019","journal-title":"Blood."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/nm.4431","article-title":"The activated conformation of integrin B7 is a novel multiple myeloma-specific target for CAR T cell therapy","volume":"23","author":"Hosen","year":"2017","journal-title":"Nat. Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1080\/21645515.2015.1046658","article-title":"CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma","volume":"11","author":"Yousef","year":"2015","journal-title":"Hum Vaccines Immunother."},{"key":"B136","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1182\/blood.V130.Suppl\/1.3142.3142","article-title":"Chimeric antigen receptor (CAR) T cells specific for CD229: a potentially curative approach for multiple myeloma","volume":"130","author":"Venniyil Radhakrishnan","year":"2017","journal-title":"Blood."},{"key":"B137","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat Commun."},{"key":"B138","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1182\/blood-2019-121967","article-title":"B cell maturation antigen-specific CAR T cells for relapsed or refractory multiple myeloma: a meta-analysis","volume":"134","author":"Gagelmann","year":"2019","journal-title":"Blood."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred cd20\/cd19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"key":"B140","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40259-019-00354-5","article-title":"Immunogenicity of chimeric antigen receptor T-cell therapeutics","volume":"33","author":"Gorovits","year":"2019","journal-title":"Bio Drugs Clin Immunother Biopharm Gene Ther."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to address chimeric antigen receptor tonic signaling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"B142","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"B144","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","article-title":"Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent","volume":"21","author":"Gomes-Silva","year":"2017","journal-title":"Cell Rep."},{"key":"B145","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.V128.22.2127.2127","article-title":"A novel Bcma-specific, centyrin-based CAR-T product for the treatment of multiple myeloma","volume":"128","author":"Hermanson","year":"2016","journal-title":"Blood."},{"key":"B146","doi-asserted-by":"publisher","first-page":"e1253656","DOI":"10.1080\/2162402X.2016.1253656","article-title":"Fine-tuning the CAR spacer improves T-cell potency","volume":"5","author":"Watanabe","year":"2016","journal-title":"Oncoimmunology."},{"key":"B147","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B148","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 ligand-modified chimeric antigen receptor t cells enhance antitumor function by eliciting an endogenous antitumor response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell."},{"key":"B149","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking Sc Fv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia."},{"key":"B151","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1182\/blood-2019-122513","article-title":"Identification and validation of predictive biomarkers to CD19- and BCMA-Specific CAR T-cell responses in CAR T-cell precursors","volume":"134","author":"Wang","year":"2019","journal-title":"Blood."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","article-title":"PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified t cells","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia."},{"key":"B153","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fimmu.2016.00112","article-title":"Marrow-infiltrating lymphocytes - role in biology and cancer therapy","volume":"7","author":"Borrello","year":"2016","journal-title":"Front. Immunol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1182\/blood-2019-130629","article-title":"Superior efficacy of CAR-T cells using marrow-infiltrating lymphocytes (MILs TM) as compared to peripheral blood lymphocytes (PBLs)","volume":"134","author":"Lutz","year":"2019","journal-title":"Blood."},{"key":"B155","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature."},{"key":"B156","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"key":"B157","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-Shelf\u201d allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"B158","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood-2018-99-119227","article-title":"ALLO-715, an allogeneic BCMA CAR T therapy possessing an off-switch for the treatment of multiple myeloma","volume":"132","author":"Sommer","year":"2018","journal-title":"Blood."},{"key":"B159","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1182\/blood-2019-131839","article-title":"Manufacture of an allogeneic CAR-T stem cell memory product candidate for multiple myeloma, P-Bcma-ALLO1, is robust, reproducible and highly scalable","volume":"134","author":"Cranert","year":"2019","journal-title":"Blood."},{"key":"B160","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1182\/blood-2018-99-112544","article-title":"A protein-based method to develop allogeneic chimeric antigen receptor T-cells","volume":"132","author":"Maciocia","year":"2018","journal-title":"Blood."},{"key":"B161","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.4049\/jimmunol.174.5.2591","article-title":"CD8+ T cell immunity against a tumor\/self-antigen is augmented by CD4+ t helper cells and hindered by naturally occurring t regulatory cells","volume":"174","author":"Antony","year":"2005","journal-title":"J Immunol Baltim Md."},{"key":"B162","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","article-title":"CAR-T efficacy: is conditioning the key?","volume":"133","author":"Neelapu","year":"2019","journal-title":"Blood."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia."},{"key":"B166","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.3324\/haematol.2017.178947","article-title":"Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance","volume":"103","author":"Danhof","year":"2018","journal-title":"Haematologica."},{"key":"B167","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv."},{"key":"B168","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1002\/1097-0142(197712)40:6<2765::aid-cncr2820400602>3.0.co;2-x","article-title":"Combination therapy for multiple myeloma","volume":"40","author":"Alexanian","year":"1977","journal-title":"Cancer."},{"key":"B169","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B170","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1182\/blood-2018-99-119514","article-title":"PD-1 inhibitor combinations as salvage therapy for relapsed\/refractory multiple myeloma (MM) patients progressing after Bcma-directed CAR T cells","volume":"132","author":"Bernabei","year":"2018","journal-title":"Blood."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","article-title":"BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy","volume":"7","author":"Smith","year":"2019","journal-title":"Cancer Immunol Res."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"B174","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1158\/1078-0432.CCR-19-1479","article-title":"Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors","volume":"25","author":"Balakrishnan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B175","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood."},{"key":"B176","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/leu.2017.302","article-title":"A compound chimeric antigen receptor strategy for targeting multiple myeloma","volume":"32","author":"Chen","year":"2018","journal-title":"Leukemia."},{"key":"B177","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 Bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun."},{"key":"B178","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1182\/blood-2019-131056","article-title":"Bcma X, and CD19 Bispecific CAR-T for relapsed and refractory multiple myeloma","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood."},{"key":"B179","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia."},{"key":"B180","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1182\/blood-2017-03-770776","article-title":"Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab","volume":"129","author":"Garc\u00eda-Guerrero","year":"2017","journal-title":"Blood."},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0840-y","article-title":"Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab","author":"Garc\u00eda-Guerrero","year":"2020","journal-title":"Leukemia."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood."},{"key":"B183","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1182\/blood-2019-129405","article-title":"Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase bcma surface expression in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Cowan","year":"2019","journal-title":"Blood."},{"key":"B184","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl."},{"key":"B187","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"Hema Sphere."},{"key":"B188","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-Cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica."},{"key":"B190","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B191","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"Mosser","year":"2008","journal-title":"Nat Rev Immunol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood."},{"key":"B193","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 Blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med."},{"key":"B194","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood."},{"key":"B195","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood."},{"key":"B197","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist."},{"key":"B198","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med."},{"key":"B199","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"B200","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"B201","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov."},{"key":"B202","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrclinonc.2018.19","article-title":"Toxicity management after chimeric antigen receptor T Cell therapy: one size does not fit \u201cALL.\u201d","volume":"15","author":"Teachey","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"B204","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"B205","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest."},{"key":"B206","doi-asserted-by":"publisher","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med."},{"key":"B207","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature."},{"key":"B208","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/ejh.13380","article-title":"B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis","volume":"104","author":"Gagelmann","year":"2020","journal-title":"Eur J Haematol."},{"key":"B209","first-page":"140","article-title":"Revlimid (lenalidomide) now FDA approved as first-line therapy for patients with multiple myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am Health Drug Benefits."},{"key":"B210","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet."},{"key":"B211","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.3324\/haematol.2018.205476","article-title":"Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the carthadex trial","volume":"104","author":"Wester","year":"2019","journal-title":"Haematologica."},{"key":"B212","year":"2018","journal-title":"Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value"},{"key":"B213","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","article-title":"Cost effectiveness of chimeric antigen receptor t-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T06:20:43Z","timestamp":1595917243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":213,"alternative-id":["10.3389\/fonc.2020.01243"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01243","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"article-number":"1243"}}